Stock Traders Buy High Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock investors bought 4,583 call options on the stock. This represents an increase of approximately 61% compared to the typical volume of 2,839 call options.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC lifted its position in Sangamo Therapeutics by 12.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company's stock worth $125,000 after buying an additional 13,518 shares in the last quarter. LPL Financial LLC lifted its position in Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 16,498 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Sangamo Therapeutics by 4.5% during the 4th quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company's stock valued at $406,000 after purchasing an additional 17,049 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 21,793 shares in the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at $25,000. Hedge funds and other institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Trading Up 4.4%

SGMO stock traded up $0.02 during midday trading on Friday, reaching $0.47. The company had a trading volume of 5,907,196 shares, compared to its average volume of 8,744,642. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18. The company has a market capitalization of $107.72 million, a P/E ratio of -0.63 and a beta of 1.46. The company has a 50 day moving average of $0.73 and a two-hundred day moving average of $1.32.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $6.44 million during the quarter, compared to analysts' expectations of $7.90 million. On average, sell-side analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Truist Financial decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Barclays decreased their price objective on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $4.50.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.